



Application No. (if known): 10/820,099


Attorney Docket No.: 61190(50221)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 756266860 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on March 30, 2006
Date


Eileen M Woodbury

Signature

Eileen M. Woodbury

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 439-4444

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)

IDS (Citation) by Applicant (1 page)

Cited Reference (10)

Notification of Transmittal of the International Search Report and the
Written Opinion of the international Searching Authority, or the Declaration
(8 pages)

Notification of Transmittal of the Internaiton Prelimianry Report on
Patentability (15 pages)



4-9-06

JFW

Docket No.: 61190(50221)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Simon McEwen

Application No.: 10/820,099

Confirmation No.: 8281

Filed: April 7, 2004

Art Unit: 1614

For: THERAPEUTIC COMPOSITION FOR
AUTOIMMUNE CONDITIONS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicant invites the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. The listed references were cited in the International Search Report issued in the International application PCT/GB2004/001562, filed April 7, 2004, which corresponds to the instant application. Copies of the Search Report citing these documents and a copy of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant understands the Examiner will make an independent evaluation of the cited documents.

Applicant respectfully requests that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 61190(50221). A duplicate copy of this paper is enclosed.

Dated: March 30, 2006

Respectfully submitted,

By 

Melissa Hunter-Ensor, Ph.D.

Registration No.: 55,289

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/820,099-Conf. #8281
				Filing Date	April 7, 2004
				First Named Inventor	Simon McEwen
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	61190(50221)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP-1 228 767 A				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Cantani, et al., "Enzyme-Potentiated Desensitization in Children with Asthma and Mite Allergy: A Double-Blind Study", Journal of Investigational Allergology and Clinical Immunology, 6(4):270-276, 1996.		
	CB	Egger, et al., "Controlled Trial of Hyposensitization in Children with Food-Induced Hyperkinetic Syndrome", Lancet 339(8802):1150-1153, 1992.		
	CC	McEwen, et al., "Enzyme-potentiated Hyposensitization. 3. Control by Sugars and Diols of the Immunological Effect of Beta Glucuronidase in Mice and Patients with Hay Fever", Annals of Allergy 31(11):543-550, 1993.		
	CD	Menge, et al., "Monoclonal Autoantibodies from Patients with Autoimmune Diseases: Specificity, Affinity and Crossreactivity of Mabs Binding to Cytoskeletal and Nucleolar Epitopes, Cartilage Antigens and Mycobacterial heat-Shock Protein 60", Immunobiology 205(1):1-16, 2002.		
	CE	Wang, et al., "The influence of HLA-DR4 (0401) on the immune response to type 11 Collagen and the Development of Collagen Induced Arthritis in Mice", Journal of Autoimmunity 18(2):95-103, 2002.		
	CF	Matteson, E.L., "Current Treatment Strategies for Rheumatoid Arthritis: Mayo Clinic Proceedings, Mayo Medical Ventures 75(1):69-74, 2000.		
	CG	Vischer, T.L., "Oral Desensitization in the Treatment of Human Immune Diseases" Zeitschrift Fuer Rheumatologie, 54(3):155-157 1995.		
	CH	Targoni, et al., "Prevention of Murine EAE by Oral Hydrolytic Enzyme Treatment" Journal of Autoimmunity, 12(3):191-198 1999.		
	CI	LIGAND: 3.2.1.31, www.genome.ad.jp/dbget-bin/www_bget?ligand+3.2.1.31		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--